|
|
Press release
MaaT Pharma Publishes its Half Year 2023 Results and
Provides a Business Update
• The ARES study on MaaT013 reached the required patient threshold for DSMB1 planning in
early Q4.23
• The European Medicines Agency EMA has granted MaaT033 orphan drug designation
aiming to improve overall survival in patients undergoing HSCT2
• ... Lire le communiqué |
|
| |
|
| |
|
|
Information mensuelle relative au nombre total de
droits de vote et dactions composant le capital social
Article 22316 du Règlement Général de lAutorité des Marchés Financiers
Lyon, France, 8 septembre 2023 – 18h00 CET – MaaT Pharma EURONEXT : MAAT la
« Société », société de biotechnologies en stade clinique avancé, leader dans le
développement de Microbiome... Lire le communiqué |
|
| |
|
| |
|
|
Monthly Information Regarding the Total Number of
Voting Rights and Shares Comprising the Share Capital
Article 22316 of the General Regulations of the Financial Markets Authority
AMF Autorité des Marchés Financiers
Lyon, France, September 8, 2023 6:00 pm CET – MaaT Pharma EURONEXT: MAAT – the
“Company”, a clinicalstage biotechnology company and... Lire le communiqué |
|
| |
|
| |
|
|
Press release
MaaT Pharma Announces European Medicines Agency
Granted MaaT033 Orphan Drug Designation aiming to
improve overall survival in patients undergoing
Hematopoietic Stem Cell transplantation
• MaaT033 capsule, which is being developed as an adjunctive and maintenance
therapy to improve overall survival in alloHSCT, has received orphan drug... Lire le communiqué |
|
| |
|
| |
|
|
Communiqué de presse
MaaT Pharma annonce que l’Agence Européenne des
Médicaments a accordé la désignation de médicament
orphelin à MaaT033 visant à améliorer la survie globale
des patients ayant reçu une greffe de cellules souches
hématopoïétiques
• MaaT033 capsule, actuellement développé comme traitement adjuvant pour
améliorer... Lire le communiqué |
|
| |
|
| |
|
|
MaaT Pharma: Halfyear Report on Liquidity Contract
With the Brokerage Firm Kepler Cheuvreux
Lyon, France, July 13, 2023 – 6:00 pm CET – MaaT Pharma EURONEXT: MAAT – the “Company”, a
French clinicalstage biotech and a pioneer in the development of Microbiome Ecosystem
TherapiesTM MET dedicated to improving survival outcomes for patients with cancer, today
announces its halfyear... Lire le communiqué |
|
| |
|
| |
|
|
Draft Press release
MaaT Pharma Announces New Appointments to the
Board and Executive Team
• Appointments to the Board of Directors and Executive team, to align with the
Company’s longterm vision and goals:
o Karim Dabbagh as Chairman and Nadia Kamal as Director, both
independent.
o Pr. Gervais Tougas,... Lire le communiqué |
|
| |
|
| |
